linjc16/ctgov huggingface dataset:
Epileptogenic Focus Localization for Children With Epilepsy Using 18F-FDG PET Molecular Imaging

Study Overview
=================
Brief Summary
-----------------
This retrospective study aimed to develop a new approach for automatic localization of epilepsy foci in children with epilepsy.

Detailed Description
-----------------
This retrospective study aimed to develop a new approach for automatic localization of epilepsy foci in children with intractable epilepsy. Pediatric patients with intractable epilepsy would be retrospectively included in this study. The inclusion criteria included (1) age between 6 and 18 y; (2) detailed seizure semiology evaluation, MRI, EEG and interictal 18F-FDG PET/CT examination; (3) clinical diagnosis as focal epilepsy. The exclusion criteria included (a) any history of central nervous system disease; (b) poor image quality due to head movement.

Official Title
-----------------
Epileptogenic Focus Localization for Children With Epilepsy Using 18F-FDG PET Molecular Imaging

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Radiation: 18F-FDG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. age between 6 and 18 years. 2. detailed presurgical evaluation, including seizure semiology evaluation, MRI, EEG and interictal 18F-FDG PET/Computer Tomography (CT) examination. 3. clinical diagnosis as focal epilepsy. Exclusion Criteria: 1. any history of central nervous system (CNS) disease such as trauma and CNS tumor. 2. poor image quality due to head movement.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Epilepsy patients<br>Pediatric patients with focal epilepsy. | Radiation: 18F-FDG<br>* All subjects received 18F-FDG PET examination.<br>|
| Control<br>Age-matched controls who underwent 18F-FDG PET/CT examination for diseases outside brains. | Radiation: 18F-FDG<br>* All subjects received 18F-FDG PET examination.<br>|
| Validation<br>Children who underwent 18F-FDG PET/MRI to examine extracranial tumors. | Radiation: 18F-FDG<br>* All subjects received 18F-FDG PET examination.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy | The accuracy of epilepsy focus localization. | Through study completion, about 6 months | 
| Kappa | The agreement between experiment result and clinical diagnosis. | Through study completion, about 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Epilepsy, Peidatrics, Positron emission tomography (PET)
Prediction of Acute Kidney Injury After Operation of Acute Type A Aortic Dissection Based on Multimodal Model

Study Overview
=================
Brief Summary
-----------------
Acute kidney injury is one of the most common postoperative complications of acute type A aortic dissection, which is closely related to early postoperative death. Early prevention, early diagnosis and early treatment are the key to improve the prognosis of such patients. It has been a hot topic in clinical research for a long time. Previous reports revealed a series of risk factors for acute kidney injury after aortic dissection, but limited by research design and single modal data, high quality studies were rare. The purpose of this study is to further clarify the risk factors by studying the relationship between preoperative CT renal perfusion imaging indexes and postoperative acute kidney injury; establish and externally verify the multimodal radiomics prediction model for acute kidney injury after operation of aortic dissection combining with preoperative CT renal perfusion imaging and CT angiography information by analysis methods of information fusion, feature engineering and radiomics, so as to guide the follow-up clinical practice, improve the prognosis of such patients and save medical resources.

Official Title
-----------------
Prediction of Acute Kidney Injury After Operation of Acute Type A Aortic Dissection Based on Multimodal Model

Conditions
-----------------
Aneurysm, Dissecting, Acute Kidney Injury

Intervention / Treatment
-----------------
* Diagnostic Test: Normal CT Renal Perfusion imaging indexes
* Diagnostic Test: Low CT Renal Perfusion imaging indexes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-70 years old Acute type A aortic dissection diagnosed by CT angiography Sign informed consent Exclusion Criteria: History of chronic kidney disease History of cardiovascular operation Acute kidney injury has occurred before operation Pregnancy status

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal Perfusion<br> | Diagnostic Test: Normal CT Renal Perfusion imaging indexes<br>* A CT imaging which indicates the status of renal perfusion is normal.<br>|
| Low Perfusion<br> | Diagnostic Test: Low CT Renal Perfusion imaging indexes<br>* A CT imaging which indicates the status of renal perfusion is low.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute kidney injury after operation | Yes; No | From date of operation until the date of acute kidney injury or date of death from any cause, whichever came first, assessed up to 30 days. |
Lung Aeration During WEANing From Mechanical Ventilation Determined by Electrical Impedance Tomography and Lung Ultrasound

Study Overview
=================
Brief Summary
-----------------
Evaluation of lung aeration during weaning from mechanical ventilation determined by electrical impedance tomography and lung ultrasound

Detailed Description
-----------------
Prospective clinical study in ICU with patients during weaning from mechanical ventilation comparing lung aeration determined by electrical impedance tomography and lung ultrasound. Duration of weaning test is 60 minutes.

Official Title
-----------------
Lung Aeration During WEANing From Mechanical Ventilation Determined by Electrical Impedance Tomography and Lung Ultrasound

Conditions
-----------------
Critical Care, Weaning From Mechanical Ventilation, Electrical Impedance Tomography, End Expiratory Lung Volume, Lung Ultrasound Score

Intervention / Treatment
-----------------
* Other: - Weaning from mechanical ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult ICU patients during weaning test from mechanical ventilation Consent of patients or family Arterial line Exclusion Criteria: Tracheotomized patients Dressings in the thoracic area

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: - Weaning from mechanical ventilation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| End-expiratory lung volume (EELV) | End-expiratory lung volume (EELV) determined by electrical impedance tomography at baseline (start of the weaning test) | at baseline | 
| End-expiratory lung volume (EELV) | - End-expiratory lung volume (EELV) determined by electrical impedance tomography at Hour 1 (end of the weaning test). | at hour 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anterior, medio-anterior, medio-posterior and posterior EELV |  | at baseline (start of the weaning test) | 
| Lung ultrasound score |  | at baseline (start of the weaning test) | 
| Anterior, medio-anterior, medio-posterior and posterior EELV |  | at Hour 1 (end of the weaning test).. | 
| Lung ultrasound score |  | at Hour 1 (end of the weaning test).. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Critical Care, Non invasive ventilation, Electrical impedance tomography, End expiratory lung volume, Lung ultrasound score
IRIS- DESyne X2 in the IRIS-DES Registry

Study Overview
=================
Brief Summary
-----------------
This study evaluates effectiveness and safety of DESyne X2 in Routine Clinical Practice.

Official Title
-----------------
Evaluation of Effectiveness and Safety of DESyne X2 in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Conditions
-----------------
Coronary Stenosis, Coronary Occlusion, Coronary Disease

Intervention / Treatment
-----------------
* Device: DESyne X2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 19 and more Intervention with DeSyne X2 drug-eluting coronary stent Agreed with written informed consent form Exclusion Criteria: Intervention with DeSyne X2 drug-eluting coronary stent and other drug eluting stent at the same time Life expectancy of 1year and under Cardiac shock

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Coronary stenosis<br> | Device: DESyne X2<br>* Novolimus-eluting stent<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite event rate | Death, non-fatal myocardial infarction, Target Vessel Revascularization | 1year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All death |  | 5years | 
| Cardiac death |  | 5years | 
| Myocardial infarction |  | 5years | 
| Composite event of death or myocardial infarction |  | 5years | 
| Composite event of cardiac death or myocardial infarction |  | 5years | 
| Target Vessel revascularization |  | 5years | 
| Target Lesion revascularization |  | 5years | 
| Stent thrombosis | stent thrombosis as classified by an Academic Research Consortium | 5years | 
| Stroke |  | 5years | 
| Procedural success | defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days. | 3days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PCI, DES, real world
Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to provide new information and to determine which kinds of brief, tolerable, experimental pain are affected by the drugs being studied in patients with irritable bowel syndrome, a disease that causes chronic abdominal pain. The effects of dextromethorphan, naloxone, and fentanyl on experimental pain stimuli will be tested in these studies to better understand what causes irritable bowel syndrome.

Official Title
-----------------
Central Nervous System Modulation of Visceral Pain in Persian Gulf War Syndrome

Conditions
-----------------
Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Procedure: Viceral Perception Testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients with irritable bowel syndrome and healthy pain-free individuals (as controls) will be studied. No medical condition that would contraindicate use of dextromethorphan, fentanyl or naloxone.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Viceral Perception Testing|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Irritable Bowel Syndrome, Visceral Hypersensitivity, Visceral Pain
Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients

Study Overview
=================
Brief Summary
-----------------
Investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients

Official Title
-----------------
Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients - A Pilot Study

Conditions
-----------------
Autoimmune Encephalopathy

Intervention / Treatment
-----------------
* Drug: Vigabatrin 500 MG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-85 Possible autoimmune encephalitis Patients who have been diagnosed and treated for encephalitis for more than 4 weeks Patients with epilepsy (EEG finding or clinically) Exclusion Criteria: septic shock, fever >38.5 ℃, O2 saturation <90%, respiratory rate >25, HR >120 previously, mRS=3 or mRS>3 MMSE<20 Patients who have terminal disease eye problem pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vigabatrin treatment group<br> | Drug: Vigabatrin 500 MG<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Seizure frequency reduction | 50% reduction - favorable outcome | 3 month of vigabatrin administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Rankin Scale |  | 3 month of vigabatrin administration | 
| Quality of life (Quality of Life in Epilepsy Inventory, QOLIE-31) |  | after 3 month of vigabatrin administration | 
| Depression (Beck Depression Inventory®-II) |  | 3 month of vigabatrin administration | 
| Cognition (Mini-Mental State Examination-Korean) |  | 3 month of vigabatrin administration | 
| Sleep quality (Pittsburgh Sleep Quality Assessment) |  | 3 month of vigabatrin administration |
Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

Study Overview
=================
Brief Summary
-----------------
To compare the pharmacokinetic (PK) profile of TR-700 in elderly subjects versus younger control subjects

Detailed Description
-----------------
This is an open-label Phase 1 study of a single oral tablet of TR-701 FA 200 mg to compare the TR-700 PK profile in elderly subjects (age 65 years and older, with at least 5 subjects 75 years old or older) and younger control subjects (age 18 to 45 years).

Official Title
-----------------
A Phase 1 Open-Label Study With Oral TR-701 Free Acid to Assess Pharmacokinetics, Safety, and Tolerability in Elderly Subjects

Conditions
-----------------
Healthy Subjects

Intervention / Treatment
-----------------
* Drug: TR-701 FA 200 mg
* Drug: TR-701 FA 200 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female subjects in the following groups: An elderly subject at least 65 years of age. At least 5 subjects must be at least 75 years of age OR A matched-control subject between 18 and 45 years of age, inclusive BMI ≥18.0 kg/m2 and ≤35.0 kg/m2 Elderly Group Medical history, physical examination, and laboratory results consistent with stable health (as determined by the Investigator) Control Group Medically stable with no clinically significant abnormalities Exclusion Criteria: Significant, uncontrolled, or life-threatening condition or organ or system condition or disease (eg, impaired cognitive status, respiratory insufficiency, advanced malnutrition) Positive hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus antibody test result Previous inclusion in a TR-701 FA or TR-701 clinical study ECG finding of QTc interval >500 msec, or other clinically significant ECG abnormality at Screening Female subjects whom are pregnant, lactating or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Elderly subjects (65 or older)<br> | Drug: TR-701 FA 200 mg<br>* Single oral tablet of TR-701 FA to elderly subjects<br>|
| Experimental: Younger adults (18-45 years old)<br> | Drug: TR-701 FA 200 mg<br>* Single oral tablet of TR-701 FA to younger group (18-45 years old)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare PK profile of TR-700 FA in elderly subjects versus younger control subjects |  | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
volunteer
Vaginal Cuff Dehiscence at Total Laparoscopic Hysterectomy

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess a major complication of total laparoscopic hysterectomy, vaginal dehiscence, with two different colpotomy techniques. With this aim patients to be operated for laparoscopic hysterectomy will be randomized to two different techniques. The colpotomy will be undertaken by 'cut mode' in the first group and 'coagulation mode' in the second group. All of the operations will be preformed by the same surgical at a university hospital. Vaginal dehiscence after surgery is the primary outcome measure.

Official Title
-----------------
Vaginal Cuff Dehiscence After Two Different Colpotomy Techniques at Total Laparoscopic Hysterectomy; a Randomized Clinical Trial

Conditions
-----------------
Surgical Wound Dehiscence

Intervention / Treatment
-----------------
* Device: Monopolar needle electrode


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All total laparoscopic hysterectomies performed by a single surgeon Both benign and malignant cases Completed laparoscopically Intracorporeal vaginal cuff suturing Exclusion Criteria: Robotic hysterectomies Pelvic infection within 30 days before surgery Conversion to laparotomy
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Coagulation mode<br>Colpotomy will be performed by monopolar needle electrode using coagulation mode | Device: Monopolar needle electrode<br>* Colpotomy during total laparoscopic hysterectomy<br>|
| Active Comparator: Cut mode<br>Colpotomy will be performed by monopolar needle electrode using cut mode | Device: Monopolar needle electrode<br>* Colpotomy during total laparoscopic hysterectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaginal dehiscence | Vaginal dehiscence up to 3 months after surgery | 3 months |
Influence of Multidisciplinary Breast Tumor Board on Physician Decision

Study Overview
=================
Brief Summary
-----------------
In our study, the treatment plan for the case prior to the breast tumor counseling will be asked to physician and the treatment protocol observed by the primary physician will be observed after the decision of the tumor council.

Official Title
-----------------
Influence of Multidisciplinary Breast Tutor Board on Physician Clinical Decision

Conditions
-----------------
Breast Cancer, Breast Neoplasms, Surgery, Oncology

Intervention / Treatment
-----------------
* Other: Breast cancer treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients having primary breast cancer Exclusion Criteria: Patients having recurrent breast cancer -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>Patients treated according to suggestions of tumor board | Other: Breast cancer treatment<br>* Multidisciplinary approach for breast cancer treatment is more beneficial for the patients<br>|
| Group B<br>Patients not treated according to suggestions of tumor board | Other: Breast cancer treatment<br>* Multidisciplinary approach for breast cancer treatment is more beneficial for the patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Better survival | Multidisciplinary approach creates better survival | 2 years |